7380 COCA COLA DRIVE, HANOVER, MD
Amended material disclosure
Ex-99.1
Dr. Sian Bigora Transitions to Part-Time Role at Processa Pharmaceuticals
End of Material Contract
Processa Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price
1-for-25 Reverse Stock Split Approved for Processa Pharmaceuticals
News
Q1
Amended Annual Report
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
S-1
Direct Registration System
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
PRER14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence